We like the LA Times’ Booster Shots blog. We really do.
But if the paper insists on being brief in its blog posts, at least it could provide links to provide more context and to plug holes in what is reported briefly on the blog.
So, for example, it would require only a few words to address these flaws:
Again, we appreciate the existence of the Booster Shots blog. But this was a bad day.
Migraine is not a topic to fool around with. People who have this problem may gravitate toward any news of progress. We think they deserved more scrutiny of claims and more context than they got in this piece.
No mention of costs – and none of these devices is cheap.
The story explains that 39% of patients who received the real device had at least a 50% decrease in the number of headaches per month.
Why not say that this was 10 patients? And why not give us the precise absolute number – not the relative risk reduction – of how many headaches?
More importantly, no mention is made of any difference between the rate of response in subjects given the real treatment and those provided a sham treatment. Did the sham treatment result in a significant improvement as well?
Also not good enough.
The story explained that "the most common side effect was migration of the leads" but it didn’t explain how common that was. Was it 100% of the time? 50% What does common mean?
And it didn’t explain how bothersome that was to people. Was it like a hiccup? Did it hurt?
Finally, the editorial to which the story refers points out that even if this technology works (and we don’t know that it does), the "complication rates would need to be reduced" if it is to be acceptable. We don’t know why that didn’t make it into the story.
Not good enough.
Yes, the story said this was "a small pilot study" and yes it said "if the results can be confirmed…."
But why not explicitly state how limited are the conclusions that can be drawn from a study of only 33 people who got the device?
And, given that the funding for the study came from the manufacturer, readers should be told what safeguards were in place against bias. How do they know this study has any validity?
The description of migraine given in the story is too broad: "characterized by severe pain accompanied by nausea and sensitivity to light…" Any severe headache can be accompanied by nausea and photophobia. The readers do not know from this description whether they are fellow sufferers or not. And perhaps more important: a careful reading of the editorial that accompanies the study demonstrates that the study participants were a highly rarified subgroup of more general migraine sufferers. These subjects had to have migraine in the same area that the occipital nerve travels and had to respond to some tests of the occipital nerve. Therefore, the story does the reader a disservice by neglecting to qualify to whom this study might apply.
OK. Medtronic’s funding of the study is disclosed. Minimal independent input was achieved by citing what an editorial writer wrote.
Inadequate in comparing this device with the range of alternatives the 14% of uncontrolled migraine sufferers pursue. This device was described as "one such approach." What are the others? How do they compare?
The reader would not be able to figure out from the story whether this is an experimental device or something already on the market. And, if on the market, how widespread is its use? Yes, the first paragraph says "If the results can be confirmed, the approach could provide another tool…" and perhaps savvy readers would read into this that the approach is not yet available. But there is no clear, explicit statement on availability. It would only require a few words.
Inadequate in explaining the range of alternatives the 14% of uncontrolled migraine sufferers pursue. This device was described as "one such approach." What are the others? How do they compare? How truly novel is this, if at all?
Not applicable because we can’t be sure of the extent to which the story relied on a news release. There is no quote from an interview. The lead author isn’t quoted at all. An accompanying editorial is cited.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like